NASDAQ: MDXG
MIMEDX GROUP, INC.CIK 0001376339 · SIC 3841 · Surgical & Medical Instruments
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (NX 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade MDXG commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Jul 29, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except share and per share data)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Net sales | 64,362 | 98,605 | 123,353 | 186,810 |
| Cost of sales | 19,981 | 18,681 | 37,348 | 35,239 |
| Gross profit | 44,381 | 79,924 | 86,005 | 151,571 |
| Operating expenses: | ||||
| Selling, general and administrative | 59,779 | 64,151 | 113,010 | 124,120 |
| Research and development | 2,777 | 3,303 | 6,917 | 6,632 |
| Amortization of intangible assets | 291 | 100 | 592 | 199 |
| Operating income | (18,466) | 12,370 | (34,514) | 20,620 |
| Other expense, net | ||||
| Interest income, net | 788 | 738 | 1,673 | 1,244 |
| Other expense, net | (102) | (101) | (270) | (247) |
| (Loss) income before income tax | (17,780) | 13,007 | (33,111) | 21,617 |
| Income tax benefit (provision) | 2,940 | (3,389) | 7,411 | (4,978) |
| Net (loss) income | (14,840) | 9,618 | (25,700) | 16,639 |
| Basic net (loss) income per common share | (0.10) | 0.07 | (0.17) | 0.11 |
| Diluted net (loss) income per common share | (0.10) | 0.06 | (0.17) | 0.11 |
| Weighted average common shares outstanding basic | 147,795,741 | 147,761,332 | 148,119,083 | 147,518,179 |
| Weighted average common shares outstanding diluted | 147,795,741 | 149,317,281 | 148,119,083 | 149,529,544 |
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share data)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 135,839 | 166,121 |
| Accounts receivable, net | 41,297 | 75,707 |
| Inventory | 20,931 | 25,340 |
| Other current assets | 7,298 | 10,303 |
| Total current assets | 205,365 | 277,471 |
| Property and equipment, net | 4,914 | 4,713 |
| Deferred tax asset, net | 27,295 | 19,596 |
| Goodwill | 19,441 | 19,441 |
| Intangible assets, net | 12,086 | 14,158 |
| Other assets | 11,897 | 7,274 |
| Total assets | 280,998 | 342,653 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Current portion of long term debt | 1,500 | 1,500 |
| Accounts payable | 8,293 | 14,528 |
| Accrued compensation | 13,175 | 31,065 |
| Accrued expenses | 11,140 | 11,383 |
| Other current liabilities | 4,390 | 5,790 |
| Total current liabilities | 38,498 | 64,266 |
| Long term debt, net | 15,706 | 16,467 |
| Other liabilities | 10,791 | 5,372 |
| Total liabilities | 64,995 | 86,105 |
| Stockholders' equity | ||
| Common stock; $0.001 par value; 250,000,000 shares authorized; 149,188,840 issued and 145,724,441 outstanding at June 30, 2026 and 148,093,920 issued and outstanding at December 31, 2025 | 149 | 148 |
| Additional paid-in capital | 297,094 | 299,081 |
| Treasury stock at cost; 3,464,399 shares at June 30, 2026 and 0 shares at December 31, 2025 | (12,859) | — |
| Accumulated deficit | (68,381) | (42,681) |
| Total stockholders' equity | 216,003 | 256,548 |
| Total liabilities and stockholders’ equity | 280,998 | 342,653 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net (loss) income | (25,700) | 16,639 |
| Adjustments to reconcile net (loss) income to net cash flows provided by operating activities | ||
| Depreciation and amortization | 3,148 | 6,371 |
| Credit loss expense | 6,745 | 1,093 |
| Non-cash lease expenses | 664 | 619 |
| Share-based compensation | (793) | 9,014 |
| Deferred income taxes | (7,699) | 908 |
| Other | 222 | 294 |
| Increase (decrease) in cash resulting from changes in: | ||
| Accounts receivable | 27,664 | (14,493) |
| Inventory | 4,409 | (1,083) |
| Other assets | 3,282 | (2,106) |
| Accounts payable | (1,234) | 792 |
| Accrued compensation | (17,055) | (791) |
| Accrued expenses | (157) | 3,528 |
| Other liabilities | (1,632) | (1,067) |
| Net cash flows (used in) provided by operating activities | (8,136) | 19,718 |
| Cash flows from investing activities: | ||
| Cash paid for acquisitions | (5,000) | (700) |
| Purchases of equipment | (1,168) | (556) |
| Patent application costs | (109) | (37) |
| Net cash flows used in investing activities | (6,277) | (1,293) |
| Cash flows from financing activities: | ||
| Cash paid for share repurchases pursuant to Share Repurchase Plan | (12,468) | — |
| Stock repurchased for tax withholdings on vesting of restricted stock | (2,028) | (2,984) |
| Principal payments on Citizens Term Loan Facility | (750) | (500) |
| Cash paid for Profit Share Payment (Note 12) | (607) | (488) |
| Deferred financing cost | (16) | — |
| Net cash flows used in financing activities | (15,869) | (3,972) |
| Net change in cash | (30,282) | 14,453 |
| Cash and cash equivalents, beginning of period | 166,121 | 104,416 |
| Cash and cash equivalents, end of period | 135,839 | 118,869 |
Amounts as printed on the EDGAR/iXBRL face — (in thousands, except share and per share data); (in thousands, except share data); (in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗